OMRF has answered the call for personal protective equipment donations and is joining the Covid-19 testing efforts.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF’s Clinical Genomics Center will now be able to offer services to clinicians.
The project is focused on lupus, which affects up to 1.5 million Americans.
Patient volunteers like Phyllis Smith are vital to the drug trial process.